GSK $30B investment aims to expand US manufacturing, countering global pricing challenges.
Browsing: Market & Financials
Market trends, financial performance, quarterly results, and investment insights from global pharma and biotech companies.
LB Pharmaceuticals IPO raises $285M, marking the first major biotech IPO since February, focusing on schizophrenia treatment.
Takeda appoints Rhonda Pacheco to lead its U.S. business, leveraging her experience with Zepbound’s launch.
Novo Nordisk layoffs affect 9,000 employees globally as part of restructuring to address obesity drug competition.
Merck cancels London lab plans, citing $1.3B investment issues and lack of UK government progress.
Gilead AI manufacturing hub breaks ground in US, creating over 3,000 jobs and boosting biopharma innovation.
Enveda Biosciences funding reaches $300M to develop drugs for immune and obesity conditions, including atopic dermatitis and asthma.
Pharma industry executives expect the recent GST rate cut to serve as a booster for contract manufacturers, while on the issue of input tax credit (ITC) — arising from the 18 per tax on APIs — leaders suggest that faster processing of refunds could help to recover the invested capital and ease tax liability.
Cipla Q1 earnings beat forecast, leading to a rise in shares. The financial performance highlights growth in India.
Amgen to build $600m science and innovation centre in the US